<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To examine the role of soluble Fas (sFas) in patients with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e>'s <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We measured the sFas levels in both sera and aqueous humor (AH) of patients (n = 40) with <z:hpo ids='HP_0000554'>uveitis</z:hpo> and of non-<z:hpo ids='HP_0000554'>uveitis</z:hpo> controls (n = 27) using an enzyme-linked immunosorbent assay </plain></SENT>
<SENT sid="2" pm="."><plain>The patients with <z:hpo ids='HP_0000554'>uveitis</z:hpo> comprised 24 with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e>, 6 pan-<z:hpo ids='HP_0000554'>uveitis</z:hpo>, 5 <z:hpo ids='HP_0012122'>anterior uveitis</z:hpo>, 2 lens-induced <z:hpo ids='HP_0000554'>uveitis</z:hpo>, 1 Vogt-Koyanagi-<z:e sem="disease" ids="C0042170" disease_type="Disease or Syndrome" abbrv="">Harada disease</z:e>, 1 sarcoidosis, and 1 retinal <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The severity of <z:hpo ids='HP_0000554'>uveitis</z:hpo> was determined by the Hogan grading method (0--4 grade) at the time of sampling </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The concentration of aqueous sFas in <z:hpo ids='HP_0000554'>uveitis</z:hpo> patients was significantly higher than that in non-<z:hpo ids='HP_0000554'>uveitis</z:hpo> controls, while there was no difference in the serum concentration of sFas between the two groups </plain></SENT>
<SENT sid="5" pm="."><plain>In the paired samples of serum and AH, obtained simultaneously, the aqueous sFas levels were higher than serum Fas levels in patients with <z:hpo ids='HP_0000554'>uveitis</z:hpo>, whereas the non-<z:hpo ids='HP_0000554'>uveitis</z:hpo> controls displayed significantly lower sFas levels in AH than in the serum </plain></SENT>
<SENT sid="6" pm="."><plain>The sFas levels in AH or serum were not different between <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e>'s <z:hpo ids='HP_0000554'>uveitis</z:hpo> patients and non-<z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e>'s <z:hpo ids='HP_0000554'>uveitis</z:hpo> patients </plain></SENT>
<SENT sid="7" pm="."><plain>However, in patients with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e>'s <z:hpo ids='HP_0000554'>uveitis</z:hpo>, circulating sFas strongly correlated with aqueous sFas, which was not so in those with non-<z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e>'s <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Patients (n = 29) with more active (grade greater-than-or-equal 2) <z:hpo ids='HP_0000554'>uveitis</z:hpo> had significantly higher levels of aqueous sFas than those (n = 11) with less active (grade &lt; 2) <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>After treatment with steroids and/or <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi>, aqueous sFas levels decreased in parallel with a reduction in the number of inflammatory cells </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The levels of sFas were elevated in patients with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e>'s <z:hpo ids='HP_0000554'>uveitis</z:hpo> and correlated well with the <z:hpo ids='HP_0000554'>uveitis</z:hpo> severity in these patients </plain></SENT>
</text></document>